Longevity Health (XAGE) and Its Peers Head to Head Analysis

Insider & Institutional Ownership

24.2% of Longevity Health shares are owned by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by institutional investors. 29.0% of Longevity Health shares are owned by company insiders. Comparatively, 18.1% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Longevity Health and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Longevity Health	-682.67%	N/A	-261.90%
Longevity Health Competitors	-672.41%	-133.75%	-59.01%

Earnings & Valuation

This table compares Longevity Health and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Longevity Health	$1.05 million	-$10.37 million	-0.08
Longevity Health Competitors	$59.55 million	-$32.15 million	4.18

Longevity Health’s peers have higher revenue, but lower earnings than Longevity Health. Longevity Health is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Longevity Health has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. Comparatively, Longevity Health’s peers have a beta of 1.76, suggesting that their average share price is 76% more volatile than the S&P 500.

Summary

Longevity Health peers beat Longevity Health on 5 of the 9 factors compared.

Longevity Health Company Profile

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.